Prostatype Genomics application process for cost reimbursement at Medicare in the US is proceeding as planned. The company expects approval in the second half of 2025. Medicare is the largest insurer for prostate cancer patients in the US with 60 percent of the market. Prostatype has applied for reimbursement of $3 per test under an existing reimbursement code. The company has already begun billing private insurance companies and is ready to launch with laboratory partners and regulatory approvals in place.
|
Published August 29, 2025
Prostatype Genomics updates on Medicare application
Notes
OssDsign signs agreement in the western US
Annexin doses first patients in phase IIa study
Boule Diagnostics CEO leaves the company
Flerie divests Limited Partnership segment
Cantargia reports survival results from TRIFOUR
Guard Therapeutics explores strategic options
Thor Medical signs supply agreement with RadioMedix
NEWSLETTER
Today's news roundup
The news sweep Friday 05 December
Upcoming events
MedTech Summit 2026
A new, much-needed MedTech forum in one of Europe's leading life science clusters. As the first event of its kind...
Global Forum 2026
This May, our premier event returns, dramatically expanded yet carefully curated to ensure a welcoming and high-value experience. We ha...
Investing in Life Science
Set in vibrant Stockholm, the Swedish finance capital, this boutique investor event connects regional life science leaders looking for strategic...
Recommended
BiBBInstruments validates clinical need during US tour
Sunstone sounds the alarm: “Danish startups are running on fumes”
Sprint Bioscience: "We have shown it is possible to make early deals"
How to take medtech to market – tips from those who have succeeded
Flerie seeks to merge with Lipum – creating a private platform for the next development phase of SOL-116
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account